C. R. Bard, Inc.

Mercator Medsystems, Inc.

Other

W. L. Gore & Associates, Inc.

Medtronic Vascular, Inc.

National Institutes of Health, a Component of the US Dept. of Health & Human Services

The United States of America

Reviticell Holdings, Inc.

Robert L Cafferata

Larry K Keefer

Kirk Patrick Seward

Anthony L Fitzhugh

Lynn Mateel Barr

Richard A Gambale

Stephen J Forcucci

Richard T Choh

Judith Carol Wilber

Marc Hendriks

Peiwen Cheng

Eugene Tedeschi

Stephanie M Kladakis

Joseph Saavedra

John D Murray

Leslie E Frilling

Gregory G Bendis

Gary A Granfield

Michel I P M Verhoeven

Michel L P M Verhoeven

Disclosed herein are standardized and optimized, modular single-use kits and methods for sterile or non-sterile preparation of biological material, such as cells or tissue, for immediate use, further preparation, or storage. These single-use kits and methods facilitate and improve a healthcare practitioner's ability to prepare biological material for research, diagnostic and therapeutic purposes in a convenient, consistent, repeatable, safe and effective manner.

Modular single-use kits and methods for preparation of biological material

Methods and systems for regenerating damaged tissue rely on direct injection of selected therapeutic cells into a tissue at or near the site of tissue damage. Direct injection is accomplished using an intravascular catheter having a deployable needle, and injection is usually targeted into the adventitial and peri-adventitial tissues surrounding the blood vessel from which the needle is deployed.

Methods and systems for treating ischemic tissues

Methods and kits for delivering pharmaceutical agents to the adventitia and other regions outside the external elastic lamina (EEL) surrounding a blood vessel utilize a catheter having a needle. The needle is positioned in up to 5 mm beyond the EEL and delivers an amount of pharmaceutical agent sufficient to circumferentially permeate around the blood vessel and, in many cases, extend longitudinally and radially along the blood vessel. Confirmation that a delivery aperture of the needle lies beyond the EEL may be required before delivering the pharmaceutical agent.

Methods and kits for volumetric distribution of pharmaceutical agents via the vascular adventitia and microcirculation

The invention provides a cardiovascular occluder for treating a cardiovascular abnormality comprising a frame and an alarmin or an alarmin activator bound to the surface of the frame. The invention further provides methods of manufacturing the cardiovascular occluder and methods of treating cardiovascular abnormalities by delivering the cardiovascular occluder.

Intracardiac implant for delivery of alarmins and methods thereof

A collapsible wild fire fighting water bucket made from pliable material and suspended from an aircraft to be lowered into an open body of water for filling. A weighted Rim Opening Device holds the bucket top open for filling and facilitates a tipping over action during filling. The buckets open top being free of any centrally located supports. The bucket is equipped with a tubular extension which forms a discharge port for dumping water. The tubular extension being releasably supported under water inside the bucket under tension. Purse lines running through openings in the tubular extension and resilient sealing lips bring sealing lip bulbs into abutment sealing the discharge port of the tubular extension. Suspension lines suspend the bucket from the aircraft and a releasable support, releasably supports the free end of the tubular extension within the bucket body extending upwardly from the openings to close the discharge port. The releasable support cooperates with the openings to allow the tubular extension to be rapidly lowered so as to extend downwardly from the bottom to open the discharge port for dumping the water. The purse lines cooperate with the releasable support to lift and lower the tubular extension. The buckets also are equipped with emergency extractor Jump Seats, secured to the inside wall of the bucket to be used for dire straits emergency extraction of wild fire ground crews trapped by fire storm.

Helicopter water bucket improvements

Extremely hydrophobic nitric oxide (NO) releasing polymers are disclosed. The extremely hydrophobic NO-releasing polymers provided are extensively cross-linked polyamine-derivatized divinylbenzene diazeniumdiolates. These polymers can be loaded with extremely high NO levels and designed to release NO in manners than mimic natural biological systems. The NO-releasing extremely hydrophobic polymers provided can maintain a sustained NO release for periods exceeding nine months. Also provided are related medical devices made using these NO-releasing extremely hydrophobic polymers.

Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use

Biocompatible metallic medical devices having silanized surfaces coupled to nucleophile residues that release sustained, therapeutic amounts of nitric oxide to specific sites within a mammalian body are provided. Additionally, the biocompatible metallic medical devices can also be provided with anti-thrombogenic, lubricious coatings that release sustained, therapeutic amounts of nitric oxide. Moreover, the silanized metallic devices are surprisingly durable when exposed to harsh chemical methods often needed to bind nitric oxide-releasing functional groups to nucleophile residues. Furthermore, methods are provided for producing stable, silanized, sustained nitric oxide-releasing metallic medical devices.

Nitric oxide-releasing metallic medical devices

The present invention provides a transthoracic drug delivery device that utilizes pressure to determine the precise location of the distal tip of the delivery tube of the device to insure that therapeutic substances are ejected into the myocardium and not dissipated in unintended tissue locations. In one embodiment the drug delivery device comprises a pressure sensing tube mounted in parallel to a drug delivery tube wherein the tubes are staggered so that the pressure tube extends beyond the delivery tube. When the myocardium is penetrated by the tubes, advancement into the heart and penetration into the left ventricle by the pressure sensing tube results in a pressure increase that indicates to the physician that the drug delivery tube, by its placement relative to the pressure sensing tube is still in the myocardium and, thus, prepared to deliver the drug. In another embodiment, a steerable syringe is provided so that multiple sites in the myocardium can be treated with a therapeutic substance with only one penetration into the heart. Once the delivery tube of the syringe penetrates the left ventricle, its distal tip can be deflected back toward the endocardial surface and the tube withdrawn proximally to cause penetration of the tip into the myocardium. A pressure sensor mounted to the tube indicates, by a measured drop in pressure that the myocardium has been penetrated. The therapeutic substance is ejected into the myocardium and the device is then backed out of the tissue by advancing the syringe in a distal direction. The deflectable tip can be adjusted to a different deflection angle and the delivery tube rotated to make available a circular array of points that may be accessed by the syringe.

Transthoracic drug delivery device

A system and method for implanting pellets into myocardial tissue for treatment of coronary artery restenosis, ischemic heart disease, or cardiac conduction of disturbances. The mechanism of delivery can be transcatheter via chambers of the heart, endoscopic pericardial approach via minimally invasive transthoracic access, or intraoperative pericardial approach during open-chest surgery. Noncardiac tissues can also be treated.

Systems and methods for treating ischemia

The present invention provides a transthoracic drug delivery device that utilizes pressure to determine the precise location of the distal tip of the delivery tube of the device to insure that therapeutic substances are ejected into the myocardium and not dissipated in unintended tissue locations. In one embodiment the drug delivery device comprises a pressure sensing tube mounted in parallel to a drug delivery tube wherein the tubes are staggered so that the pressure tube extends beyond the delivery tube. When the myocardium is penetrated by the tubes, advancement into the heart and penetration into the left ventricle by the pressures sensing tube results in a pressure increase that indicates to the physician that the drug delivery tube, by its placement relative to the pressure sensing tube is still in the myocardium and, thus, prepared to deliver the drug. In another embodiment, a steerable syringe is provided so that multiple sites in the myocardium can be treated with a therapeutic substance with only one penetration into the heart. Once the delivery tube of the syringe penetrates the left ventricle, its distal tip can be deflected back toward the endocardial surface and the tube withdrawn proximally to cause penetration of the tip into the myocardium. A pressure sensor mounted to the tube indicates, by a measured drop in pressure that the myocardium has been penetrated. The therapeutic substance is ejected into the myocardium and the device is then backed out of the tissue by advancing the syringe in a distal direction. The deflectable tip can be adjusted to a different deflection angle and the delivery tube rotated to make available a circular array of points that may be accessed by the syringe.

Growing community of inventors

Santa Rosa, CA, United States of America

Robert L Cafferata